Tirzepatide

99%+ Purity USA Tested

Research Use Only. Not for Human or Veterinary Use

Tirzepatide: Dual GIP/GLP-1 receptor agonist, CAS 2023788-19-2, MW 4813.45 g/mol, ≥99% purity. Lyophilized powder for laboratory use.

Price range: $90.00 through $160.00

Peptide Name	Tirzepatide (LY3298176)
CAS Number	2023788-19-2
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	4813.45 g/mol
Mechanism Class	Dual GIP/GLP-1 receptor agonist
Appearance	White lyophilized powder
Purity	≥99% (HPLC)
Storage	-20°C, desiccated, protected from light
Solubility	Soluble in sterile water or DMSO

This product is not intended for human or animal use. For scientific research only.

VivePeptides provides detailed analytical results including High-Performance Liquid Chromatography (HPLC) and mass spectrometry data for all peptides. These reports confirm peptide purity, composition, and molecular accuracy, giving researchers full transparency and confidence in the materials used for their studies.

VIEW COA

VivePeptides peptides should be stored in a cool, dry environment and protected from light and moisture. Lyophilized peptides are best kept refrigerated or frozen until use to maintain stability. Once reconstituted for research purposes, peptides should be stored according to standard laboratory protocols, typically under refrigeration, and handled using proper aseptic techniques to preserve integrity throughout the study period.

OVERVIEW

What Is Tirzepatide Peptide?

Tirzepatide is a synthetic 39-amino-acid peptide designed as a dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Built on a native GIP backbone sequence, tirzepatide peptide incorporates specific modifications that enable it to activate both incretin receptor pathways simultaneously. This dual mechanism has made tirzepatide research peptide one of the most significant compounds in modern metabolic research.

The tirzepatide peptide features an aminoisobutyric acid (Aib) substitution at position 2 for DPP-4 resistance and a C-20 fatty diacid moiety linked to lysine-20, facilitating albumin binding and an extended half-life in research models. As a tirzepatide research chemical, it represents a novel approach to studying incretin biology by engaging both the GIP and GLP-1 receptor systems, a strategy that has generated considerable interest in the peptide research community.

Dual GIP/GLP-1 Receptor Agonist

Synthetic 39-amino acid peptide targeting both incretin receptors

≥99% HPLC Purity

Every batch verified via high-performance liquid chromatography

USA Tested & Verified

Third-party analytical testing performed in USA laboratories

RESEARCH

Tirzepatide Mechanism of Action in Research

The tirzepatide mechanism of action involves simultaneous activation of two distinct incretin receptor pathways — a feature that distinguishes it from single-agonist compounds like semaglutide. Tirzepatide research has revealed complex receptor pharmacology that continues to be investigated in preclinical models.

GIP Receptor Agonism

Tirzepatide was designed on a native GIP backbone and demonstrates potent GIP receptor agonism. In research models, GIP receptor activation by tirzepatide has been observed to influence lipid metabolism, adipose tissue function, and bone metabolism pathways. Studies suggest that tirzepatide’s GIP receptor activity may be a key differentiating factor in its research profile. Published data indicate that tirzepatide demonstrates approximately equal potency at the GIP receptor compared to native GIP (Coskun et al., Molecular Metabolism, 2018).

GLP-1 Receptor Agonism

In addition to GIP receptor activity, tirzepatide research peptide activates the GLP-1 receptor, engaging the same cAMP-mediated signaling cascades studied with selective GLP-1 agonists. The tirzepatide GIP GLP-1 dual activation is thought to produce complementary and potentially synergistic effects in research settings. Studies indicate tirzepatide’s GLP-1 receptor potency is approximately 5-fold lower than native GLP-1, suggesting a biased agonism profile.

Biased Agonism and Receptor Pharmacology

Emerging tirzepatide research has explored the concept of biased agonism at both receptor targets. Studies suggest tirzepatide may preferentially activate certain intracellular signaling pathways over others at each receptor, potentially explaining its distinct pharmacological profile. This area of investigation represents a frontier in incretin receptor biology research. —

COMPARISON

Tirzepatide vs Retatrutide: Research Peptide Comparison

Tirzepatide and retatrutide represent the evolution of multi-receptor agonist peptide research. While tirzepatide is a dual GIP/GLP-1 agonist, retatrutide adds a third target — the glucagon receptor — creating a triple agonist profile.

Feature	Tirzepatide	Retatrutide
Receptor Targets	GIP + GLP-1 (dual agonist)	GIP + GLP-1 + Glucagon (triple agonist)
CAS Number	2023788-19-2	2381089-83-2
Molecular Weight	4813.45 Da	~4803.75 Da
Amino Acids	39	39
Backbone	GIP-based	GIP-based
Receptor Count	2	3
Research Stage	Extensively published	Emerging research compound
Key Differentiator	Established dual agonist research profile	Addition of glucagon receptor activity

Both tirzepatide research peptide and retatrutide are available from VivePeptides at ≥99% purity. Researchers investigating dual incretin signaling typically choose tirzepatide, while those studying the added dimension of glucagon receptor co-agonism may opt for retatrutide.

RESEARCH STUDIES

Tirzepatide Research Applications & Published Studies

Tirzepatide research grade compound has been the subject of rapidly growing preclinical and research literature, with studies published in leading scientific journals examining its dual receptor pharmacology.

Incretin Receptor Pharmacology

Foundational tirzepatide research by Coskun et al. (Molecular Metabolism, 2018) characterized its dual receptor agonism, establishing that tirzepatide demonstrates imbalanced agonism at the GIP and GLP-1 receptors. This research demonstrated that tirzepatide’s GIP-to-GLP-1 potency ratio differs from the 1:1 balance, suggesting a unique pharmacological profile that warrants specific investigation.

Metabolic Pathway Studies

Tirzepatide research has included extensive investigation of metabolic pathways in animal models. Studies have documented effects on glucose-stimulated insulin secretion, hepatic lipid metabolism, and energy expenditure parameters in rodent models. Published research indicates that dual GIP/GLP-1 receptor activation may engage metabolic pathways not accessible through single-receptor agonism alone.

Adipose Tissue Biology

A growing area of tirzepatide research focuses on adipose tissue biology. Published studies have examined how dual incretin receptor activation influences adipocyte differentiation, lipid storage, and adipokine expression patterns. These investigations leverage tirzepatide’s unique GIP receptor activity, as GIP receptors are expressed in adipose tissue.

QUALITY ASSURANCE

Quality & Testing Standards

VivePeptides ensures every batch of tirzepatide research peptide meets the highest analytical standards.

HPLC & Mass Spectrometry

Every tirzepatide batch undergoes HPLC and mass spectrometry analysis to confirm peptide identity, purity, and correct molecular weight.

Third-Party Verified

All tirzepatide is independently tested at third-party USA-based analytical laboratories with full documentation.

≥99% Purity Standard

VivePeptides tirzepatide consistently meets or exceeds ≥99% purity as verified by HPLC for reliable research outcomes.

FAQ

Frequently Asked Questions About Tirzepatide

What is tirzepatide used for in research?

Tirzepatide is used in preclinical research to study dual incretin receptor signaling, GIP and GLP-1 receptor pharmacology, metabolic pathway regulation, and adipose tissue biology. It is sold for research use only and is not intended for human or veterinary use.

What purity is VivePeptides tirzepatide?

VivePeptides tirzepatide research peptide is manufactured to ≥99% purity as confirmed by HPLC analysis. Every batch undergoes independent testing at USA-based analytical laboratories.

How should tirzepatide be stored?

Lyophilized tirzepatide should be stored at -20°C, protected from light and moisture. Reconstituted solutions should be stored at 2–8°C and used within 7 days. Avoid repeated freeze-thaw cycles.

What makes tirzepatide different from semaglutide in research?

Tirzepatide is a dual GIP/GLP-1 receptor agonist built on a GIP backbone, while semaglutide is a selective GLP-1 receptor agonist based on the GLP-1 sequence. This structural difference means tirzepatide engages additional receptor pathways not accessed by semaglutide alone.

Is VivePeptides tirzepatide third-party tested?

Yes. Every lot of VivePeptides tirzepatide undergoes independent third-party testing at USA-based laboratories, including HPLC purity analysis and mass spectrometry identity verification. Results are available for qualified researchers.

Related Research Peptides

Explore other research-grade peptides available from VivePeptides. Each product meets the same rigorous purity and testing standards.

Semaglutide

Selective GLP-1 receptor agonist for incretin pathway research

Retatrutide

Triple agonist peptide targeting GIP, GLP-1, and glucagon receptors

KLOW Blend

Premium weight management peptide blend for metabolic research

Tesamorelin

GHRH analog for growth hormone research

Explore More Research Peptides

All Peptides → · BPC-157 · CJC-1295 No DAC + Ipamorelin · MOTS-c · NAD+ · GHK-Cu · Semax · BAC Water